OBJECTIVE: The optimal dose of stereotactic body radiotherapy (SBRT) for metastatic lung tumors has not been clarified. Local control rates of metastatic lung tumors treated with SBRT of 48 Gy in four fractions, which is one of the common dose schedules for Stage I primary lung cancer in Japan, were examined. METHODS: Between 2006 and 2008, 12 metastatic lung tumors (colorectal cancer, 7; others, 5) in 10 patients and 56 lesions of Stage I primary lung cancer (T1, 43; T2, 13) in 52 patients were treated with SBRT of 48 Gy in four fractions at the isocenter. RESULTS: Two-year overall survival rates were 86% for patients with metastatic lung tumors and 96% for patients with Stage I primary lung cancer (P = 0.4773). One- and 2-year local control rates were 48% and 25% for metastatic lung tumors, and 91% and 88% for Stage I primary lung cancer, respectively (P < 0.0001). CONCLUSIONS: The local control rates after SBRT of 48 Gy in four fractions were significantly worse in metastatic lung tumors compared with Stage I primary lung cancer. In SBRT, metastatic lung tumors should be clearly differentiated from primary lung cancer and should be given higher doses.
OBJECTIVE: The optimal dose of stereotactic body radiotherapy (SBRT) for metastatic lung tumors has not been clarified. Local control rates of metastatic lung tumors treated with SBRT of 48 Gy in four fractions, which is one of the common dose schedules for Stage I primary lung cancer in Japan, were examined. METHODS: Between 2006 and 2008, 12 metastatic lung tumors (colorectal cancer, 7; others, 5) in 10 patients and 56 lesions of Stage I primary lung cancer (T1, 43; T2, 13) in 52 patients were treated with SBRT of 48 Gy in four fractions at the isocenter. RESULTS: Two-year overall survival rates were 86% for patients with metastatic lung tumors and 96% for patients with Stage I primary lung cancer (P = 0.4773). One- and 2-year local control rates were 48% and 25% for metastatic lung tumors, and 91% and 88% for Stage I primary lung cancer, respectively (P < 0.0001). CONCLUSIONS: The local control rates after SBRT of 48 Gy in four fractions were significantly worse in metastatic lung tumors compared with Stage I primary lung cancer. In SBRT, metastatic lung tumors should be clearly differentiated from primary lung cancer and should be given higher doses.
Authors: Deepinder Singh; Yuhchyau Chen; Mary Z Hare; Kenneth Y Usuki; Hong Zhang; Thomas Lundquist; Neil Joyce; Michael C Schell; Michael T Milano Journal: J Thorac Dis Date: 2014-04 Impact factor: 2.895
Authors: Daniel Kim; Mark M Fuster; Sameer K Nath; Anjali Bharne; William Read; Lyudmilla Bazhenova; William Y Song; Arno J Mundt; Ajay P Sandhu Journal: J Radiosurg SBRT Date: 2012
Authors: Alina Mihai; Yijia Mu; John Armstrong; Mary Dunne; Sushil Beriwal; Luke Rock; Pierre Thirion; Dwight E Heron; Brian Healy Bird; Jennifer Westrup; Conleth Gerard Murphy; M Saiful Huq; Raymond McDermott Journal: J Radiosurg SBRT Date: 2017
Authors: Daniel Kim; Mark M Fuster; Sameer K Nath; Anjali Bharne; William Read; Lyudmilla Bazhenova; William Y Song; Arno J Mundt; Ajay P Sandhu Journal: J Radiosurg SBRT Date: 2012
Authors: Percy Lee; Billy W Loo; Tithi Biswas; George X Ding; Issam M El Naqa; Andrew Jackson; Feng-Ming Kong; Tamara LaCouture; Moyed Miften; Timothy Solberg; Wolfgang A Tome; An Tai; Ellen Yorke; X Allen Li Journal: Int J Radiat Oncol Biol Phys Date: 2019-04-05 Impact factor: 8.013
Authors: Marco D'Arienzo; Stefano G Masciullo; Vitaliana de Sanctis; Mattia F Osti; Laura Chiacchiararelli; Riccardo M Enrici Journal: Int J Environ Res Public Health Date: 2012-11-19 Impact factor: 3.390